GARDEN CITY, N.Y. and REHOVOT, Israel, July 15, 2019 -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing.

GARDEN CITY, N.Y. and REHOVOT, Israel, June 17, 2019 -- AIT Therapeutics, Inc. (NASDAQ: AITB), a clinical-stage medical device and biopharmaceutical company focused on.

Announces name change to Beyond Air™ Completed uplisting to the NASDAQ and $7.96 million PIPE financing Anticipate PMA submission in the third quarter of calendar 2019.

Announces name change to Beyond Air™ Completed uplisting to the NASDAQ and $7.96 million PIPE financing Anticipate PMA submission in the third quarter of calendar 2019.

AIT Therapeutics, Inc. (AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, today announced that it has successfully executed funding agreements to raise $8 million through a private investment in public equity (PIPE) financing.

AIT Therapeutics Inc. is a clinical-stage medical device and biopharmaceutical company developing a revolutionary NO Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The AIT NO Delivery System can generate up to 400 ppm of NO for delivery either continuously or for a fixed amount of time and has the ability to either titrate dose on demand or maintain a constant dose.  The Company is currently applying its therapeutic expertise to develop treatments for pulmonary hypertension in various settings, in addition to treatments for lower respiratory tract infections that are not effectively addressed with current standards of care.